title: Genetic and proteomic approaches to identify cancer drug targets.
abstract: While target-based small-molecule discovery has taken centre-stage in the pharmaceutical industry, there are many cancer-promoting proteins not easily addressed with a traditional target-based screening approach. In order to address this problem, as well as to identify modulators of biological states in the absence of knowing the protein target of the state switch, alternative phenotypic screening approaches, such as gene expression-based and high-content imaging, have been developed. With this renewed interest in phenotypic screening, however, comes the challenge of identifying the binding protein target(s) of small-molecule hits. Emerging technologies have the potential to improve the process of target identification. In this review, we discuss the application of genomic (gene expression-based), genetic (short hairpin RNA and open reading frame screening), and proteomic approaches to protein target identification.
authors.affiliation: Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Pediatric Hematology/Oncology, Children's Hospital Boston, Harvard Medical School, Boston, MA 02215, USA.
authors.forename: G
authors.initials: G
authors.lastname: Roti
authors.forename: K
authors.initials: K
authors.lastname: Stegmaier
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015870:Gene Expression; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D040901:Proteomics
chemical_list: D000970:Antineoplastic Agents